Inhibikase Therapeutics, Inc. — Form D
Inhibikase Therapeutics, Inc. of Atlanta, GA, a company, filed a Form D exempt-offering notice with the SEC on 2023-02-07. The offering totals $4.2M, of which $4.2M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2023-02-07
- Form: D
- Accession: 0001209191-23-007563
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.2M
- Amount sold: $4.2M
- Investors: 1
- Date of first sale: 2023-01-27
- Revenue range: Decline to Disclose
- SEC file number: 021-472876
Issuer
- Name: Inhibikase Therapeutics, Inc.
- CIK: 0001750149
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 3350 RIVERWOOD PARKWAY SE, SUITE 1900, Atlanta, GA, 30339
- Phone: 678-392-3419
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Dennis Berman | Director | Atlanta, GA |
| Gisele Dion | Director | Atlanta, GA |
| Roy Freeman M.D. | Director | Atlanta, GA |
| Paul Grint, M.D. | Director | Atlanta, GA |
| Milton H. Werner Ph.D | Director | Atlanta, GA |
| Joseph Frattaroli, C.P.A. | Executive Officer | Atlanta, GA |
| Milton H. Werner Ph.D | Executive Officer | Atlanta, GA |
| Paul H Grint | Director | Atlanta, GA |
| Milton H Werner | Director | Atlanta, GA |
| Milton H Werner | Executive Officer | Atlanta, GA |
| Gisele H Dion | Director | Atlanta, GA |
| Roy H Freeman | Director | Atlanta, GA |
| Garth H Lees-Rolfe | Executive Officer | Atlanta, GA |
| Dennis H Berman | Director | Atlanta, GA |
Other filings by this issuer (1)
More